indazoles has been researched along with Airflow Obstruction, Chronic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cahn, A; Fahy, WA; Hessel, EM; Homayoun-Valiani, F; Lowings, M; Marotti, M; Meeraus, WH; Robertson, J; Tabberer, M; Templeton, A; West, SL; Wilson, R | 1 |
| Begg, M; Cahn, A; Dunsire, L; Fuhr, R; Galinanes-Garcia, L; Hamblin, JN; Hessel, EM; Kirsten, AM; Leemereise, CN; Montembault, M; Sriskantharajah, S; Watz, H; Wilson, R | 1 |
| Norman, P | 1 |
| Amour, A; Baldwin, IR; Cooper, AW; Deakin, AM; Down, K; Felton, LM; Guntrip, SB; Hamblin, JN; Hardy, C; Harrison, ZA; Jones, KL; Jones, P; Keeling, SE; Le, J; Livia, S; Lucas, F; Lunniss, CJ; Parr, NJ; Robinson, E; Rowland, P; Smith, S; Thomas, DA; Vitulli, G; Washio, Y | 1 |
| Aurivillius, M; Edsbäcker, S; Jorup, C; Kuna, P; Prothon, S; Taib, Z | 1 |
| Bonar, SL; Brustkern, SJ; Chen, NX; Christine, L; Heier, RF; Hu, Y; Huang, HC; Kishore, NN; Kurumbail, RG; Lennon, PJ; Li, X; Mathialagan, S; Poda, GI; Reding, MT; Selness, SR; Sommers, CD; Venkatraman, N; Wolfson, SG; Xie, J | 1 |
3 trial(s) available for indazoles and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.
Topics: Bronchodilator Agents; Double-Blind Method; Forced Expiratory Volume; Humans; Indazoles; Indoles; Oxazoles; Phosphatidylinositol 3-Kinases; Piperazines; Pulmonary Disease, Chronic Obstructive | 2021 |
Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.
Topics: Administration, Inhalation; Aged; Class I Phosphatidylinositol 3-Kinases; Cytokines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Indazoles; Indoles; Male; Middle Aged; Oxazoles; Piperazines; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Sputum; Treatment Outcome | 2017 |
Efficacy and Tolerability of an Inhaled Selective Glucocorticoid Receptor Modulator - AZD5423 - in Chronic Obstructive Pulmonary Disease Patients: Phase II Study Results.
Topics: Acetamides; Administration, Inhalation; Aged; Anti-Asthmatic Agents; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Indazoles; Lung; Male; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Receptors, Glucocorticoid; Time Factors; Treatment Outcome; Vital Capacity | 2017 |
3 other study(ies) available for indazoles and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423).
Topics: Acetamides; Administration, Inhalation; Animals; Asthma; Crystallization; Humans; Indazoles; Patents as Topic; Pulmonary Disease, Chronic Obstructive; Receptors, Glucocorticoid | 2013 |
Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease.
Topics: Administration, Inhalation; Animals; Asthma; Female; Humans; Indazoles; Indoles; Isoenzymes; Male; Microsomes; Molecular Docking Simulation; Ovalbumin; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pneumonia; Pulmonary Disease, Chronic Obstructive; Rabbits; Rats; Rats, Sprague-Dawley; Respiratory Tract Diseases; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Th2 Cells | 2015 |
Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationship.
Topics: Administration, Inhalation; Aminopyridines; Asthma; Binding, Competitive; Drug Design; HEK293 Cells; Humans; I-kappa B Kinase; Indazoles; Isonicotinic Acids; Microsomes, Liver; Models, Molecular; Molecular Structure; Molecular Targeted Therapy; Niacinamide; Phenethylamines; Potassium Channel Blockers; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Structure-Activity Relationship; Sulfonamides | 2011 |